Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
Theravance Biopharma (NASDAQ: TBPH) has announced that its management team will be conducting investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference. The conference is scheduled to take place from January 13-16, 2025, in San Francisco, CA. Interested investors can request one-on-one meetings with the management team by contacting the company's investor relations department.
Theravance Biopharma (NASDAQ: TBPH) ha annunciato che il suo team di gestione condurrà incontri con gli investitori durante la 43ª Conferenza Annuale J.P. Morgan Healthcare. La conferenza si terrà dal 13 al 16 gennaio 2025 a San Francisco, CA. Gli investitori interessati possono richiedere incontri individuali con il team di gestione contattando il dipartimento di relazioni con gli investitori della società.
Theravance Biopharma (NASDAQ: TBPH) ha anunciado que su equipo de gestión estará llevando a cabo reuniones con inversores durante la 43ª Conferencia Anual J.P. Morgan Healthcare. La conferencia está programada del 13 al 16 de enero de 2025 en San Francisco, CA. Los inversores interesados pueden solicitar reuniones uno a uno con el equipo de gestión contactando al departamento de relaciones con inversores de la empresa.
Theravance Biopharma (NASDAQ: TBPH)는 경영팀이 제43회 JP 모건 헬스케어 컨퍼런스 동안 투자자 회의를 진행한다고 발표했습니다. 이 컨퍼런스는 2025년 1월 13일부터 16일까지 샌프란시스코, CA에서 열릴 예정입니다. 관심이 있는 투자자들은 회사의 투자자 관계 부서에 연락하여 경영팀과 개별 회의를 요청할 수 있습니다.
Theravance Biopharma (NASDAQ: TBPH) a annoncé que son équipe de direction mènera des réunions avec les investisseurs lors de la 43e Conférence Annuelle J.P. Morgan Healthcare. La conférence se déroulera du 13 au 16 janvier 2025 à San Francisco, CA. Les investisseurs intéressés peuvent demander des réunions individuelles avec l'équipe de direction en contactant le département des relations investisseurs de l'entreprise.
Theravance Biopharma (NASDAQ: TBPH) hat bekannt gegeben, dass das Management-Team während der 43. jährlichen J.P. Morgan Healthcare-Konferenz Investorenmeetings durchführen wird. Die Konferenz ist vom 13. bis 16. Januar 2025 in San Francisco, CA, geplant. Interessierte Investoren können durch Kontaktaufnahme mit der Abteilung für Investor Relations des Unternehmens ein persönliches Treffen mit dem Management-Team anfordern.
- None.
- None.
To request a one-on-one meeting with the Theravance Biopharma management team, please contact us at investor.relations@theravance.com.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-conduct-investor-meetings-during-the-jp-morgan-43rd-annual-healthcare-conference-302333431.html
SOURCE Theravance Biopharma, Inc.
FAQ
When will Theravance Biopharma (TBPH) attend the J.P. Morgan Healthcare Conference 2025?
How can investors schedule meetings with TBPH management at the J.P. Morgan Healthcare Conference?
Where will TBPH conduct investor meetings during the J.P. Morgan Healthcare Conference 2025?
Which conference will TBPH management attend in January 2025?
